| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10485067 | Value in Health | 2012 | 6 Pages |
Abstract
The FDA continues to approve PRO claims, with 24% of new molecular entities and biologic license applications being granted. Successful PRO label claims over the past 5 years have generally supported treatment benefit for symptoms specified as primary endpoints.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Ari MSc, Margaret MS, Marci PharmD, Carla MS, Sheri PhD, Catherine MS,